WTI Crude

Loading...

Brent Crude

Loading...

Natural Gas

Loading...

Gasoline

Loading...

Heating Oil

Loading...

Rotate device for more commodity prices

James Burgess

James Burgess

James Burgess studied Business Management at the University of Nottingham. He has worked in property development, chartered surveying, marketing, law, and accounts. He has also…

More Info

The Most Promising Biotech Innovation Of 2017

CVR Medical Device

A secretive biotech company has positioned itself to potentially earn billions in revenue with the planned release of a new technology that could help prevent millions of strokes with a simple test that is affordable, non-invasive and accessible to the average American.

A Multi-Billion-Dollar Problem with a $49,000 Answer

Until now, there has been no cost-effective way to screen for Ischemia, the leading indicator of a stroke, which costs the U.S. government alone tens of billions of dollars a year. That could be about to change, thanks to a breakthrough technology from CVR Medical (TSX:CVM.V ; OTC:CRRVF) The company’s debut, game-changing medical device has been quietly in development for 10 years, and now it’s about to charge out of the gate, hoping to take the market by storm upon FDA market clearance.

CVR’s Carotid Stenotic Scan (CSS) is a tool to detect stenosis within the Carotid Arteries, potentially offering patients and caregivers a device for early detection in a quick and repeatable manner. Unlike other comparative modalities, the CSS was designed to function without the assistance of a certified technician. These three facts combine to create one of the potentially biggest—and most lucrative--phenomena in recent medical equipment market history.

The implications of this tech are unprecedented. Not only could it change the way we help prevent strokes, it’s accessibility and affordability may well transform the entire medical market.

5 Reasons Investors Should Keep A Close Eye On CVR

1. A Multi-Billion Dollar Market Place

Stroke statistics are shocking: Globally, every year 15 million people suffer a stroke. In the U.S. alone, nearly 800,000 people suffer from a stroke annually.

Currently, one out of every 20 deaths in America is caused by stroke, making this one of the most pressing medical problems of our time.

Until now, there has been no cost-effective way to screen for the leading indicator of Ischemic strokes, which cost the U.S. government alone over 34 billion dollars a year in healthcare expenses.

In the U.S., the market includes 234,615 primary care offices, specialist offices, hospitals and clinics—all of which would benefit from CVR’s affordable, non-invasive and easy-to-use technology to save millions of lives.

If these facilities bought just one CSS arterial health analysis tool each, we would be looking at over $11 billion in revenue. And that is before considering the impact of penetrating the gargantuan global market, which its uniquely affordable and accessible technology could undoubtedly do.

2. An Unrivaled Technology

Screening for Carotid Artery Stenosis, which can lead to Ischemic strokes— which represent over 80 percent of strokes – is costly and time-consuming.

CVR Medical (TSX:CVM.V ; OTC:CRRVF) believes that its diagnostic tool could not only help save millions of lives a year, but could also prevent millions of others from becoming permanently debilitated by stroke.

This pre-stroke intervention technology is not only the first economically accessible pre-stroke intervention tool out there, it’s also easy to use: It doesn’t depend on the user for accuracy and provides results in only 2 minutes.

When it takes only 2 minutes to detect Ischemia, the leading indicator of stroke, with a device that costs on average only $49,000 compared with up to $2.5 million for current technology—the market potential is phenomenal.

And on top of all of this, CVR’s all-in costs are less than half the sale costs, meaning the company is expecting a very quick and lucrative head start.

3. A Critical Time Frame For Investors

After 10 years in development, the critical time for this breakthrough technology is upon us.

CVR has invested $23 million in this technology, with early stage clinical trials complete and now headed toward pivotal trials, eyeing the potential for immediate profitability.

This means there’s only a short window of opportunity between market and profitability.

The critical timeframe is now: The release of a preliminary clinical report is pending any day, and then the full clinical report will follow in 4-8 weeks. Once that happens, the next step is FDA market clearance, and if successful, delivery to the market.

The team has already lined up manufacturing and components, so once the clinical reports are in, and the FDA hurdle is cleared, it’s breakout time.

4. A Visionary Dream Team

Led by Chairman, CEO and President Peter Bakema—with an impressive 30-year track record in business development, since its inception, CVR (TSX:CVM.V ; OTC:CRRVF) has brought on some of the most respected medical professionals in the industry.

• Tony Robinson, COO and Executive Vice-President has been with CVR for 8 years and has extensive domestic and global healthcare experience.

• Michael Rhodes, VP of Quality Systems, is a former VP for Quality for HSBC and Motorola. He has 20 years of experience in multiple markets.

• Dr. W. Douglas Weaver, a member of the BOD Scientific Advisory Board, is the former president of the American College of Cardiology and the former VP and System Medical Director of Heart and Vascular Services at Henry Ford Health System. His over 330 publications related to drug and device discovery have been some of the most influential in our time.

Together, they are on a trajectory which will revolutionize healthcare by offering easily accessible, affordable early detection for a potentially massive market share at a very critical time in our healthcare story.

5. The Definitive Year of Biotech

For biotech in general, 2017 will be the critical breakout year. For CVR Medical’s patented early stroke detection system, it will be the debut of a new technology that promises to capture the lion’s share of a multi-billion-dollar market.

While Hillary Clinton had threatened the future of biotech companies by promising to go on the offensive against them, the unexpected victory of Donald Trump has analysts heralding a very bright and very lucrative new era for biotech. Speaking to Forbes, Todd Hagopian, who manages two mutual funds through Marketocracy.com, noted that with the Republicans in control of the White House and Congress, biotechs are set up for an extraordinary comeback.

This is where the new barons are being made, with medical breakthroughs turning countless billions in new profits—and 2017 is set to be the strongest ever.

Biotech companies are going to forge lucrative new frontiers this year, from cellular immunotherapies and liquid biopsies, to bioabsorbable stents and CVR’s Carotid Stenotic Scan (CSS), which detects stenosis within the Carotid Arteries—a serious risk factor in stroke.

We are also seeing major gains this year by cellular immunotherapies reporting 90 percent remission rates for acute lymphoblastic leukemia (ALL). This should go before the FDA this year and could trigger a wave of approvals for other blood cancers and lymphomas, and could eventually replace chemotherapy. Among many other positive developments in recent years, in December 2014, Amegen (NYSE:AMGN) won FDA approval for immunotherapy Blincyto, and large-cap AstraZeneca (NYSE:AZN) is also poised for major gains in redefining cancer treatment.

Liquid biopsies, or blood tests that uncover signs of actual DNA or cell-free circulating tumor DNA (ctDNA), could prove to be a revolutionary cancer test with annual sales forecast to be $10 billion. Cancer Genetics, Inc. (NASDAQ:CGIX) now has five programs to develop and validate multi-market liquid biopsy tests. And bioabsorbable stents, approved in the U.S. in July for the first time, have an amazing market potential approaching $2 billion in six years, with this year the critical juncture. Prominent North American players in this market include Abbott (NYSE:ABT) and Reva Medical Inc. (ASX:RVA).

It’s the perfect time for a small-cap company of top-notch professionals like CVR (TSX:CVM.V ; OTC:CRRVF) to release a new medical device that everyone is desperate for—from medical professionals, to insurance providers, to the billions of people who suffer a stroke every year. It’s the perfect time for a market opportunity that’s worth billions, even without the global market.

By. James Burgess of Oilprice.com

**IMPORTANT! BY READING OUR CONTENT YOU EXPLICITLY AGREE TO THE FOLLOWING. PLEASE READ CAREFULLY**

DISCLAIMERS

PAID ADVERTISEMENT. This communication is a paid advertisement and is not a recommendation to buy or sell securities. Oilprice.com, Advanced Media Solutions Ltd, it’s owners, managers, employees, and assigns (collectively “The Company”) has been paid by a third party to disseminate this communication. This compensation is a major conflict with our ability to be unbiased, more specifically:

This communication is for entertainment purposes only. Never invest purely based on our communication. Gains mentioned in our newsletter and on our website may be based on end-of- day or intraday data. If we own any shares we will list the information relevant to the stock and number of shares here. We have been compensated by CVR Medical Corp to conduct investor relations advertising and marketing for [CVM.V]. Oilprice.com receives financial compensation to promote public companies. This compensation is a major conflict of interest in our ability to be unbiased. Therefore, this communication should be viewed as a commercial advertisement only. We have not investigated the background of the hiring third party or parties. The third party, profiled company, or their affiliates will liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Any non- compensated alerts are purely for the purpose of expanding our database for the benefit of our future financially compensated investor relations efforts. Frequently companies profiled in our alerts experience a large increase in volume and share price during the course of investor relations marketing, which often end as soon as the investor relations marketing ceases. The investor relations marketing may be as brief as one day, after which a large decrease in volume and share price is likely to occur. Our emails may contain forward looking statements, which are not guaranteed to materialize due to a variety of factors.

We do not guarantee the timeliness, accuracy, or completeness of the information on our site or in our newsletters. The information in our communications and on our website is believed to be accurate and correct, but has not been independently verified and is not guaranteed to be correct. The information is collected from public sources, such as the profiled company’s website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct. Furthermore, The Company often employs independent contractor writers who may make errors when researching information and preparing these communications regarding profiled companies. Independent writers’ works are double-checked and verified before publication, but it is certainly possible for errors or omissions to take place during editing of independent contractor writer’s communications regarding the profiled company(s). You should assume all information in all of our communications is incorrect until you personally verify the information, and again are encouraged to never invest based on the information contained in our written communications.

DISCLOSURE. The Company does not make any guarantee or warranty about what is advertised above. The Company is not affiliated with, any specific security. While the Company will not engage in front-running or trading against its own recommendations, The Company and its managers and employees reserve the right to hold possession in certain securities featured in its communications. Such positions will be disclosed AND will not purchase or sell the security for at least two (2) market days after publication.

NOT AN INVESTMENT ADVISOR. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. ALWAYS DO YOUR OWN RESEARCH and consult with a licensed investment professional before making an investment. This communication should not be used as a basis for making any investment.

INDEMNIFICATION/RELEASE OF LIABILITY. By reading this communication, you agree to the terms of this disclaimer, including, but not limited to: releasing The Company, its affiliates, assigns and successors from any and all liability, damages, and injury from the information contained in this communication. You further warrant that you are solely responsible for any financial outcome that may come from your investment decisions.

FORWARD-LOOKING STATEMENT. As defined in the United States Securities Act of 1933 Section 27(a), as amended in the Securities Exchange Act of 1934 Section 21(e), statements in this communication which are not purely historical are forward-looking statements and include statements regarding beliefs, plans, intent, predictions or other statements of future tense.

PAST PERFORMANCE IS NOT INDICATIVE OF FUTURE RESULTS. Investing is inherently risky. While a potential for rewards exists, by investing, you are putting yourself at risk. You must be aware of the risks and be willing to accept them in order to invest in any type of security. Don't trade with money you can't afford to lose. This is neither a solicitation nor an offer to Buy/Sell securities. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed on this web site. The past performance of any trading system or methodology is not necessarily indicative of future results

CFTC RULE 4.41 - HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING. ALSO, SINCE THE TRADES HAVE NOT BEEN EXECUTED, THE RESULTS MAY HAVE UNDER-OR- OVER COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFIT OR LOSSES SIMILAR TO THOSE SHOWN.

All trades, patterns, charts, systems, etc., discussed in this message and the product materials are for illustrative purposes only and not to be construed as specific advisory recommendations. All ideas and material presented are entirely those of the author and do not necessarily reflect those of the publisher. No system or methodology has ever been developed that can guarantee profits or ensure freedom from losses. No representation or implication is being made that using the methodology or system will generate profits or ensure freedom from losses. The testimonials and examples used herein are exceptional results, which do not apply to the average member, and are not intended to represent or guarantee that anyone will achieve the same or similar results.

AFFILIATES. Some or all of the content provided in this communication may be provided by an affiliate of The Company. Content provided by an affiliate may not be reviewed by the editorial staff member. Our affiliates may have their own disclosure policies that may differ from The Company’s policy.

TERMS OF USE. By reading this communication you agree that you have reviewed and fully agree to the Terms of Use found here http://oilprice.com/terms-and-conditions If you do not agree to the Terms of Use http://oilprice.com/terms-and-conditions, please contact Oilprice.com to discontinue receiving future communications.

The information contained herein may change without notice.




Back to homepage

Leave a comment
  • Josh on March 17 2017 said:
    Oil-prices

    Must continue to fall to balance demand from electric vehicle and conventional gas vehicles.
    Ultimately the performances of electric vs gas vehicles, combined with the annual cost of owning either one, will determine where the future of the oil industry goes ...
    J.

Leave a comment




Oilprice - The No. 1 Source for Oil & Energy News